Barclays’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.25B | Buy |
6,592,403
+1,100,411
| +20% | +$207M | 0.24% | 48 |
|
|
2026
Q1 | $1.08B | Buy |
5,491,992
+4,119,190
| +300% | +$794M | 0.26% | 54 |
|
|
2025
Q4 | $252M | Buy |
1,372,802
+1,029,039
| +299% | +$180M | 0.06% | 233 |
|
|
2025
Q3 | $52.7M | Buy |
343,763
+3,437
| +1% | +$520K | 0.01% | 743 |
|
|
2025
Q2 | $47.6M | Buy |
340,326
+46,278
| +16% | +$6.49M | 0.01% | 732 |
|
|
2025
Q1 | $43.2M | Sell |
294,048
-238,403
| -45% | -$34.5M | 0.01% | 698 |
|
|
2024
Q4 | $69.8M | Buy |
532,451
+301,326
| +130% | +$42.2M | 0.02% | 535 |
|
|
2024
Q3 | $36M | Sell |
231,125
-15,334
| -6% | -$2.48M | 0.01% | 807 |
|
|
2024
Q2 | $38.4M | Sell |
246,459
-199,816
| -45% | -$30.1M | 0.01% | 698 |
|
|
2024
Q1 | $60.5M | Buy |
446,275
+116,249
| +35% | +$15.4M | 0.02% | 541 |
|
|
2023
Q4 | $44.5M | Sell |
330,026
-291,190
| -47% | -$37.9M | 0.02% | 723 |
|
|
2023
Q3 | $84.1M | Buy |
621,216
+472,383
| +317% | +$64.5M | 0.05% | 355 |
|
|
2023
Q2 | $21.3M | Sell |
148,833
-4,581
| -3% | -$674K | 0.01% | 705 |
|
|
2023
Q1 | $21.3M | Sell |
153,414
-21,317
| -12% | -$2.87M | 0.01% | 816 |
|
|
2022
Q4 | $23.7M | Buy |
174,731
+112,866
| +182% | +$14.2M | 0.01% | 811 |
|
|
2022
Q3 | $6.79M | Sell |
61,865
-49,399
| -44% | -$6.27M | 0.01% | 1011 |
|
|
2022
Q2 | $14.7M | Buy |
111,264
+102,810
| +1,216% | +$13.5M | 0.01% | 848 |
|
|
2022
Q1 | $1.12M | Sell |
8,454
-201,308
| -96% | -$24.1M | ﹤0.01% | 2316 |
|
|
2021
Q4 | $24.4M | Buy |
209,762
+202,202
| +2,675% | +$23.8M | 0.01% | 873 |
|
|
2021
Q3 | $908K | Sell |
7,560
-198,158
| -96% | -$23.1M | ﹤0.01% | 2846 |
|
|
2021
Q2 | $24.6M | Buy |
205,718
+205,513
| +100,250% | +$22.5M | 0.01% | 792 |
|
|
2021
Q1 | $20K | Sell |
205
-132,357
| -100% | -$13.3M | ﹤0.01% | 4366 |
|
|
2020
Q4 | $13.3M | Buy |
132,562
+132,038
| +25,198% | +$14M | 0.01% | 1035 |
|
|
2020
Q3 | $58K | Sell |
524
-19,804
| -97% | -$2.2M | ﹤0.01% | 4520 |
|
|
2020
Q2 | $2.15M | Sell |
20,328
-30,179
| -60% | -$3.12M | ﹤0.01% | 2047 |
|
|
2020
Q1 | $4.51M | Sell |
50,507
-64,451
| -56% | -$6.07M | ﹤0.01% | 1551 |
|
|
2019
Q4 | $11.5M | Buy |
114,958
+74,029
| +181% | +$6.97M | 0.01% | 1291 |
|
|
2019
Q3 | $3.65M | Sell |
40,929
-443,688
| -92% | -$38.5M | ﹤0.01% | 2156 |
|
|
2019
Q2 | $40M | Buy |
484,617
+430,801
| +801% | +$33.8M | 0.02% | 566 |
|
|
2019
Q1 | $4.35M | Sell |
53,816
-1,742
| -3% | -$137K | ﹤0.01% | 1765 |
|
|
2018
Q4 | $4.22M | Buy |
55,558
+644
| +1% | +$50.3K | ﹤0.01% | 1708 |
|
|
2018
Q3 | $4.35M | Buy |
54,914
+1,958
| +4% | +$148K | ﹤0.01% | 1957 |
|
|
2018
Q2 | $3.72M | Sell |
52,956
-20,154
| -28% | -$1.45M | ﹤0.01% | 1981 |
|
|
2018
Q1 | $5.11M | Sell |
73,110
-22,868
| -24% | -$1.58M | ﹤0.01% | 1622 |
|
|
2017
Q4 | $6.66M | Buy |
95,978
+5,294
| +6% | +$357K | 0.01% | 1451 |
|
|
2017
Q3 | $6.14M | Sell |
90,684
-442,703
| -83% | -$28M | 0.01% | 1380 |
|
|
2017
Q2 | $36.4M | Buy |
533,387
+65,234
| +14% | +$4.26M | 0.04% | 377 |
|
|
2017
Q1 | $29.2M | Buy |
468,153
+16,016
| +4% | +$932K | 0.03% | 415 |
|
|
2016
Q4 | $24.7M | Buy |
452,137
+356,923
| +375% | +$20.3M | 0.03% | 510 |
|
|
2016
Q3 | $6.26M | Sell |
95,214
-51,002
| -35% | -$3.33M | 0.01% | 1138 |
|
|
2016
Q2 | $8.83M | Buy |
146,216
+139,736
| +2,156% | +$8.12M | 0.01% | 907 |
|
|
2016
Q1 | $362K | Sell |
6,480
-48,601
| -88% | -$2.92M | ﹤0.01% | 3389 |
|
|
2015
Q4 | $3.64M | Sell |
55,081
-52,513
| -49% | -$3.44M | ﹤0.01% | 1539 |
|
|
2015
Q3 | $6.67M | Sell |
107,594
-57,102
| -35% | -$3.76M | 0.01% | 1187 |
|
|
2015
Q2 | $10.4M | Buy |
164,696
+102,462
| +165% | +$7.02M | 0.01% | 1010 |
|
|
2015
Q1 | $4.23M | Sell |
62,234
-409,692
| -87% | -$28.5M | ﹤0.01% | 1695 |
|
|
2014
Q4 | $33M | Sell |
471,926
-652,468
| -58% | -$46.7M | 0.03% | 514 |
|
|
2014
Q3 | $79.8M | Buy |
1,124,394
+236,693
| +27% | +$17.3M | 0.08% | 206 |
|
|
2014
Q2 | $65.7M | Buy |
887,701
+768,934
| +647% | +$55.6M | 0.07% | 237 |
|
|
2014
Q1 | $7.6M | Buy |
118,767
+75,861
| +177% | +$4.9M | 0.01% | 1368 |
|
|
2013
Q4 | $2.54M | Buy |
42,906
+4,462
| +12% | +$242K | ﹤0.01% | 2420 |
|
|
2013
Q3 | $1.96M | Buy |
38,444
+1,963
| +5% | +$98.6K | ﹤0.01% | 2601 |
|
|
2013
Q2 | $1.73M | Buy |
+36,481
| New | +$1.86M | ﹤0.01% | 2710 |
|
Other funds holding AZN
EP
IA
Barclays's AZN Position: Q2 2026 in Review
Barclays increased its AstraZeneca (AZN) stake by 20% in Q2 2026, buying an estimated $207M and bringing the position to 6,592,403 shares worth $1.25B. The position accounts for 0.24% of the portfolio, ranked #48.
Barclays first reported a position in AZN in Q2 2013 and has held it in 53 quarters since. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Barclays held 6,592,403 shares of AstraZeneca worth $1.25B as of Q2 2026.
- Barclays bought 1,100,411 AstraZeneca shares in Q2 2026, an estimated $207M.
- AstraZeneca made up 0.24% of Barclays's portfolio in Q2 2026, its #48 holding.
- Barclays first reported a position in AstraZeneca in Q2 2013 and has held it in 53 quarters since.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.